[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483062":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":19,"locations":28,"responsibleParty":45,"collaborators":7,"id":47,"slug":7,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":60,"studyType":61,"phases":7,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":30,"whyStopped":7,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"IRCCS San Raffaele Roma","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution","migraine prophylaxis",[14],"anti CGRP monoclonal antibody",[16],{"name":17,"affiliation":5,"role":18},"Piero Barbanti, MD, PhD","STUDY_CHAIR",[20,24],{"name":17,"role":21,"phone":22,"phoneExt":7,"email":23},"CONTACT","+393357071457","piero.barbanti@sanraffaele.it",{"name":25,"role":21,"phone":26,"phoneExt":7,"email":27},"Cinzia Aurilia, MD","+393334147390","cinzia.aurilia@sanraffaele.it",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Roma","RM","00163","Italy",{"type":36,"coordinates":37},"Point",[38,39],11.10642,44.99364,{"lat":39,"lon":38},[42,44],{"name":17,"role":21,"phone":43,"phoneExt":7,"email":23},"0652254026",{"name":25,"role":21,"phone":43,"phoneExt":7,"email":27},{"type":46,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100483062",false,"NCT05570149","EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.","EptinezuMaB in ReAl-world evidenCE: a 12-Months, Multicenter, Real-Life, Cohort Study in High-Frequency Episodic and Chronic Migraine (the EMBRACE Study)","EMBRACE","KEY INCLUSION CRITERIA\n\n1. Age between 18 and 75 years;\n2. Males and females;\n3. Willingness to sign the informed consent;\n4. High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;\n5. Chronic migraine, according to the ICHD-III criteria;\n\nKEY EXCLUSION CRITERIA\n\n1. Other headaches different than migraine;\n2. Known intolerance to eptinezumab or eccipients;\n3. Current treatment with other mAbs;\n4. Vascular disease or Raynaud.","ALL","18 Years","75 Years",{"count":58,"type":59},500,"ESTIMATED","3 Years","OBSERVATIONAL","The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.",[64],"Migraine Disorders",[66,67,68,69,70,71,72],"Eptinezumab,","Calcitonin gene-related peptide,","Effectiveness,","Real-life,","Migraine,","Safety","Treatment","2025-04-29",{"date":75,"type":76},"2025-05-01","ACTUAL",{"date":78,"type":76},"2023-01-01",{"date":80,"type":59},"2026-12-31",{"name":5,"class":6},1]